Profile data is unavailable for this security.
About the company
Anhui Huaheng Biotechnology Co Ltd is a China-based company specializing in the research and development, production and sales of amino acids and other bio-based products based on alanine series products. The Company is a high-tech enterprise focusing on synthetic biotechnology and mainly engaged in the research and development, production and sales of amino acid and its derivative products. The Company's main products include alanine series products (L-alanine, DL-alanine, β-alanine), calcium D-pantothenate and α-arbutin. The Company's products are mainly used in the fields of medicine and health products, daily chemicals, food and food additives. The Company distributes its products and services within the domestic market and to overseas markets.
- Revenue in CNY (TTM)1.80bn
- Net income in CNY422.94m
- Incorporated2005
- Employees995.00
- LocationAnhui Huaheng Biotechnology Co LtdNo. 197 Chang'an Road, Gaoxin DistrictHEFEI 231031ChinaCHN
- Phone+86 55 165689046
- Fax+86 55 165689468
- Websitehttp://www.huahengbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liaoning Cheng Da Co Ltd | 10.39bn | 636.58m | 15.16bn | 3.41k | 23.62 | 0.5174 | -- | 1.46 | 0.4196 | 0.4196 | 6.83 | 19.15 | 0.2184 | 4.14 | 5.35 | 3,050,246.00 | 0.8825 | 4.23 | 1.30 | 6.19 | 17.92 | 13.87 | 4.04 | 9.94 | 0.8033 | -- | 0.2717 | 13.00 | -20.73 | 0.7957 | -43.34 | -3.29 | -5.20 | -3.55 |
| Jiang Zhong Pharmaceutical Co Ltd | 4.39bn | 708.29m | 15.63bn | 4.01k | 22.21 | 4.06 | -- | 3.56 | 1.12 | 1.12 | 6.94 | 6.13 | 0.7078 | 4.00 | 15.58 | 1,093,970.00 | 12.36 | 10.82 | 19.43 | 15.08 | 63.88 | 65.02 | 17.46 | 18.17 | 1.26 | -- | 0.021 | 82.88 | 13.00 | 20.12 | 18.40 | 8.54 | 11.47 | 40.99 |
| KPC Pharmaceuticals Inc | 7.70bn | 444.68m | 16.51bn | 5.05k | 37.04 | 3.12 | -- | 2.14 | 0.5885 | 0.5885 | 10.22 | 7.00 | 0.811 | 2.57 | 3.09 | 1,525,069.00 | 4.78 | 5.42 | 8.16 | 9.13 | 43.85 | 43.68 | 5.90 | 5.70 | 1.47 | -- | 0.1829 | 35.75 | -6.99 | 1.64 | 16.05 | 5.79 | -21.33 | 14.87 |
| Changchun BCHT Biotechnology Co | 1.82bn | 501.01m | 16.74bn | 1.24k | 33.41 | 4.16 | -- | 9.17 | 1.21 | 1.21 | 4.42 | 9.74 | 0.3912 | 0.978 | 1.44 | 1,470,338.00 | 10.74 | 9.95 | 13.19 | 12.81 | 89.52 | 86.63 | 27.46 | 24.03 | 2.02 | -- | 0.0051 | 10.55 | 70.30 | 12.36 | 175.98 | 31.37 | 21.04 | -- |
| Sinocelltech Group Ltd | 1.75bn | -336.34m | 17.04bn | 1.87k | -- | -- | -- | 9.73 | -0.7593 | -0.7593 | 3.95 | -0.9726 | 0.7063 | 0.3788 | 6.48 | 937,947.60 | -13.58 | -56.05 | -37.26 | -89.65 | 96.30 | 96.27 | -19.23 | -288.84 | 0.4781 | 0.8541 | 1.19 | -- | 661.33 | 179.55 | 40.13 | -- | 51.77 | -- |
| Anhui Huaheng Biotechnology Co Ltd | 1.80bn | 422.94m | 17.28bn | 995.00 | 40.70 | 10.12 | -- | 9.61 | 2.70 | 2.70 | 11.47 | 10.84 | 0.7815 | 7.71 | 9.64 | 1,808,077.00 | 18.32 | 17.86 | 24.04 | 22.29 | 39.66 | 38.67 | 23.44 | 21.49 | 0.7354 | -- | 0.2709 | 19.39 | 48.69 | 29.97 | 90.23 | 37.59 | 56.88 | -- |
| Dizal Jiangsu Pharmaceutical Co Ltd | 40.10m | -1.05bn | 17.29bn | 328.00 | -- | 15.69 | -- | 431.18 | -2.59 | -2.59 | 0.0984 | 2.65 | 0.0204 | -- | 1.52 | 122,263.40 | -53.53 | -- | -66.24 | -- | 93.97 | -- | -2,630.41 | -- | 2.02 | -- | 0.202 | -- | -100.00 | -- | -9.87 | -- | -- | -- |
| Chongqing Taiji Industry Group Co Ltd | 15.62bn | 822.12m | 17.97bn | 12.59k | 21.86 | 4.96 | -- | 1.15 | 1.48 | 1.48 | 28.05 | 6.50 | 1.07 | 3.32 | 7.83 | 1,240,976.00 | 5.82 | 0.7814 | 18.62 | 2.35 | 47.39 | 44.03 | 5.46 | 0.8498 | 0.5147 | 6.18 | 0.5658 | 25.76 | 10.58 | 7.88 | 131.99 | 63.55 | 3.86 | 24.57 |
| Shandong Buchang Pharmaceuticals Co Ltd | 13.63bn | -1.87bn | 18.22bn | 8.49k | -- | 1.49 | -- | 1.34 | -1.69 | -1.69 | 12.32 | 11.05 | 0.6087 | 1.12 | 9.71 | 1,605,200.00 | -8.86 | 4.93 | -12.07 | 7.05 | 69.25 | 77.42 | -14.56 | 7.18 | 0.5054 | -20.16 | 0.2163 | 109.43 | -5.15 | 1.52 | -218.65 | -- | -17.89 | 0.1039 |
Data as of Apr 16 2024. Currency figures normalised to Anhui Huaheng Biotechnology Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
32.88%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Bank of Communications Schroder Fund Management Co., Ltd.as of 30 Jun 2023 | 7.74m | 7.59% |
| Bosera Asset Management Co., Ltd.as of 30 Jun 2023 | 6.70m | 6.57% |
| HuaAn Fund Management Co., Ltd.as of 30 Jun 2023 | 3.97m | 3.89% |
| Da Cheng Fund Management Co., Ltd.as of 30 Jun 2023 | 3.71m | 3.64% |
| E Fund Management Co., Ltd.as of 30 Sep 2023 | 3.28m | 3.22% |
| Hwabao WP Fund Management Co., Ltd.as of 30 Jun 2023 | 2.49m | 2.45% |
| Industrial Securities Investment Management Co. Ltd.as of 30 Sep 2023 | 1.96m | 1.92% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2023 | 1.32m | 1.30% |
| CITIC Securities Co., Ltd. (Invt Port)as of 30 Jun 2023 | 1.25m | 1.23% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2023 | 1.11m | 1.09% |
More ▼
Data from 30 Jun 2023 - 10 Apr 2024Source: FactSet Research Systems Inc.
